Zum Hauptinhalt springen
Anmelden
Aktuell
my onvista
News & Analysen
News
News zu MAAT PHARMA S.A. EO-,1
Werbung ausblenden
News zu MAAT PHARMA S.A. EO-,1
MaaT Pharma and Skyepharma Have Entered a Partnership to Establish the First Exclusive Microbiome Ecosystem Therapies cGMP Manufacturing Facility in France
08.02.2022
·
18:00
Uhr · Business Wire
MaaT Pharma Announces Ordinary and Extraordinary Shareholders’ General Meeting on March 3, 2022, and the Availability of Preparatory Documents
26.01.2022
·
18:00
Uhr · Business Wire
MaaT Pharma Announces Positive Interim Engraftment Data for Oral Formulation MaaT033 Allowing Early Termination of Phase 1b CIMON Study
24.01.2022
·
07:30
Uhr · Business Wire
MaaT Pharma Provides Business Objectives and Expected Milestones for 2022
17.01.2022
·
18:00
Uhr · Business Wire
MaaT Pharma Announces Initiation of Coverage of its Stock by KBC Securities, Kempen and Portzamparc/Groupe BNP Paribas
13.01.2022
·
19:00
Uhr · Business Wire
MaaT Pharma to Present at H.C. Wainwright BioConnect 2022 Virtual Conference
03.01.2022
·
19:00
Uhr · Business Wire
MaaT Pharma Presents Promising Clinical Data from 76 Patients with Acute Graft-vs-Host-Disease Treated with MaaT013 at 63rd ASH Annual Meeting
11.12.2021
·
21:00
Uhr · Business Wire
MaaT Pharma Will Host Investor Information Meeting Following Presentation at ASH Conference of Additional Results on MaaT013
01.12.2021
·
19:30
Uhr · Business Wire
MaaT Pharma to Provide Additional Results from Phase II Trial and Expanded Access Program on MaaT013 in Oral Presentation at 63rd American Society of Hematology (ASH) Annual Meeting
09.11.2021
·
18:11
Uhr · Business Wire